Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genocea Biosciences, a vaccine discovery and development company, has entered into a cooperative research and development agreement (CRADA) with Naval Medical Research Center (NMRC) to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria.
Subscribe to our email newsletter
As per the agreement, Genocea Biosciences will receive $2.7m from the US Army Medical Research and Materiel Command (USAMRMC) for rapid T-cell antigen discovery using human T-cell screens of a P. falciparum proteomic library.
Genocea will apply its technology to the rapid identification of novel T-cell antigens from a proteomic screen of the P falciparum organism and NMRC will share materials as well as their extensive experience developing subunit malaria vaccines
Staph Leavenworth Bakali, president and CEO of Genocea Biosciences, said: “This CRADA validates our proprietary T-cell-directed antigen discovery platform technology and further strengthens our position as a leader in novel vaccine development against pathogens with a high unmet medical need.
“Our technology is uniquely suited to rapidly identifying antigens in the very large and complex P falciparum proteome that will be most likely to stimulate broad immune protection. We look forward to working with NMRC to identify such antigens that will lead to a safe and effective vaccine against malaria both for the Military and also potentially for travelers and populations living in endemic regions.”